Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 6,800 shares, an increase of 112.5% from the December 15th total of 3,200 shares. Based on an average daily trading volume, of 16,400 shares, the short-interest ratio is currently 0.4 days.
Adlai Nortye Stock Performance
NASDAQ ANL opened at $1.98 on Tuesday. The company has a fifty day moving average of $2.40 and a 200 day moving average of $2.58. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a research report on Monday, November 11th.
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- When to Sell a Stock for Profit or Loss
- Cintas: Trade Uncertainty Creates a Buy-the-Dip Opportunity
- Basic Materials Stocks Investing
- 3 Stocks to Benefit From China’s Rare Earth Export Ban on U.S.
- What Are Dividend Achievers? An Introduction
- Why Goldman Sachs Just Upgraded These 3 Stocks and What It Means
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
